Mayo Clinic launches Vancomycin clinical trial for Primary Sclerosing Cholangitis

Jan 20, 2020 | Konstantinos N. Lazaridis, M.D. | @klazaridis

2019-01-14 PSC Clinical Trial

Mayo Clinic in Minnesota, Arizona and Florida is currently conducting a randomized placebo controlled clinical trial, examining the impact of oral vancomycin on markers of cholestasis among patients with PSC. The treatment period is approximately 18 months and requires about five clinic visits along with lab draws at home.

Please contact Mr. Mitch Clayton (study coordinator) at 507-284-2698 or for additional details.

A link to the study on is provided below: 

Interested in more newsfeed posts like this? Go to the Primary Sclerosing Cholangitis (PSC) blog.

Please sign in or register to post a reply.